RECENT RELEASES
AxelaCare Holdings, Inc.-
Business
AxelaCare Holdings, Inc. (“AxelaCare”) was a leading technology-enabled provider of home infusion services for chronic and acute conditions. Therapies provided ranged from immune globulin (IG) therapy to various acute therapies including antibiotics and nutrition for patients across the United States. AxelaCare was the fifth largest and one of the fastest growing national providers of immune globulin (IG) treatment, supported by its patient-centric approach and clinical leadership.
-
Harvest Partners Investment
In April 2013, Harvest purchased AxelaCare with the existing management team. To fund the acquisition Harvest arranged the debt financing, which included a senior credit facility and a mezzanine note. Harvest sold its investment in AxelaCare to UnitedHealth Group (NYSE: UNH) in November 2015.
-
Investment Thesis
- Large, growing and fragmented industry with favorable tailwinds, including a shift toward home-based care
- Attractive, high-growth business model
- Multiple growth levers
- Strong management team with track record of success
